Interestingly, YM155 has been shown to reduce EGFR expression and tumor cell proliferation and survival in pancreatic cancer81 as well as EGFR-positive non-small cell lung cancer, in which YM155 was found to be synergistic with afatinib82 and other EGFR inhibitors83, to reverse resistance to the EGFR inhibitor erlotinib in EGFR-mutant lung cancer84, and to inhibit EGFR autophosphorylation which promotes lung cancer stemness85. This evidence concerns the gene EGFR and non-small cell lung carcinoma.